Showing 2421-2430 of 5696 results for "".
- Omeros to Sell Omidria Franchise to Rayner in a Deal Worth More Than $1 Billionhttps://modernod.com/news/omeros-to-sell-omidria-franchise-to-rayner-in-a-deal-worth-more-than-1-billion/2480488/Omeros announced that it has entered into a definitive agreement for the sale of Omidria to Rayner Surgical Group. The transaction, which is expected to close on or before December 31, 2021, includes an upfront payment of $125 million with an additional $200 million in
- Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Devicehttps://modernod.com/news/kubota-vision-announces-publication-in-scientific-reports-of-study-data-for-wearable-myopia-control-device/2480478/Kubota Vision announced the publication of a new paper in the journal Scientific Reports: Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans. The paper
- Heidelberg Engineering Receives European Acceptance for Spectralis Shift Technology Under New Medical Device Regulationhttps://modernod.com/news/heidelberg-engineering-receives-european-acceptance-for-spectralis-shift-technology-under-new-medical-device-regulation/2480442/Heidelberg Engineering announced the launch of the Spectralis platform with shift technology, which is designed to create synergies that significantly increase efficiency in both OCT and OCTA, and deliver images with more detail. Shift enables clinicians to switch between OCT scan
- CXL Ophthalmics to Present Phase 2 Clinical Trial Results in Epi-On Cross-linking on November 14 at American Academy of Ophthalmologyhttps://modernod.com/news/cxl-ophthalmics-to-present-phase-2-clinical-trial-results-in-epi-on-cross-linking-on-november-14-at-american-academy-of-ophthalmology/2480421/CXL Ophthalmics announced that the results of CXL-005, a phase 2 Trial in transepithelial (Epi-On) cross-linking, will be featured in the “Hot Topics 2021” session at AAO on November
- Novartis to Sell Roche Stake for $20.7 Billionhttps://modernod.com/news/novartis-to-sell-roche-stake-for-207-billion/2480406/Novartis said Thursday that it agreed to sell its stake in Roche for $20.7 billion, with the proceeds to be used "in line with capital allocation priorities to enhance strong returns to shareholders," according to a FirstWord repor
- Tarsus Pharmaceuticals Presents Data from Two Studies on the Prevalence and Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-data-from-two-studies-on-the-prevalence-and-impact-of-demodex-blepharitis/2480402/Tarsus Pharmaceuticals presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting in Boston. The Titan real-world prevalence study data revealed that Demodex blepharitis accounts for ov
- Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalershttps://modernod.com/news/oyster-points-tyrvaya-nasal-spray-for-dry-eye-disease-is-now-available-at-us-regional-wholesalers/2480399/Oyster Point Pharma announced that Tyrvaya (varenicline solution) Nasal Spray 0.03 mg is now available at US regional wholesalers for distribution to pharmacies. The FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on O
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- Tilak Healthcare Raises €7m to Deploy Its Remote Vision Monitoring Platformhttps://modernod.com/news/tilak-healthcare-raises-eur7m-to-deploy-its-remote-vision-monitoring-platform/2480381/Tilak Healthcare, a developer of mobile games with medical modules to monitor patients with chronic ophthalmological conditions, has announced a €7 million fundraising round managed by Elaia, with the participation of Swen Capital Partners, Matmut Innovation, and co-founder
- Collaboration Agreement Aims to Develop Orally Administered Treatment for Diabetic Macular Edema and Wet AMDhttps://modernod.com/news/collaboration-agreement-aims-to-develop-orally-administered-treatment-for-diabetic-macular-edema-and-wet-amd/2480380/Korea-based biopharmaceutical company Curacle announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation (TOI) for the development and commercialization of Curacle's CU06-RE, which is being examined as an orall